Sanofi Hopes To Improve Public Health, Profits With New Dengue Vaccine

Financial Times: Sanofi confident dengue drug will benefit patients and investors
“…[D]rugs group Sanofi has produced the world’s first vaccine for the mosquito-borne viral disease [dengue], which it expects to launch by the end of this year. While Sanofi is championing the potential public health benefits of the vaccine, the French drugmaker is also open about its commercial ambitions. … ‘The dengue vaccine will be in the high end of profitability among our vaccines,’ says Olivier Charmeil, chief executive of Sanofi Pasteur, Sanofi’s vaccines division…” (Webber et al., 7/20).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

The Henry J. Kaiser Family Foundation Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KaiserFamilyFoundation | twitter.com/kff

Filling the need for trusted information on national health issues, the Kaiser Family Foundation is a nonprofit organization based in San Francisco, California.